Please ensure Javascript is enabled for purposes of website accessibility

Why bluebird bio Stock Soared Today

By Keith Speights - Apr 9, 2020 at 3:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A major move by the Fed lifted the entire stock market, including this biotech stock.

What happened

Shares of bluebird bio (BLUE -3.66%) were soaring 9.1% higher as of 3:13 p.m. EDT on Thursday after rising as much as 10.4% earlier in the day. The nice gain came as the overall stock market jumped on news that the Federal Reserve Board announced it would inject another $2.3 trillion into the U.S. economy. 

So what

You might think Bluebird wouldn't be impacted very much by the Fed's latest effort to prop up an economy that's reeling from the COVID-19 pandemic. After all, the company only has one commercial product, transfusion-dependent beta-thalassemia drug Zynteglo, and it's not approved in the U.S. yet. 

Gloved hands holding two test tubes

Image source: Getty Images.

Even if Zynteglo and Bluebird's other experimental gene therapies were already on the market in the U.S., their success wouldn't really depend on how strong the economy is. If the company's products are safe and effective for the rare diseases they target, they're likely to be covered by payers and prescribed by physicians.

But while it doesn't seem like the biotech stock should be impacted much by the COVID-19 outbreak, the reality is that Bluebird's share price has fallen more than most stocks have during the coronavirus-fueled market decline. That's due in part to some delays in enrollment and completion of clinical trials Bluebird is conducting.

Also, the stocks of companies that are unprofitable and that don't have solid revenue streams are viewed as riskier during uncertain times. When there are signs that the uncertainty will be lower -- as we've seen today with the Fed's moves -- stocks like Bluebird often benefit the most.

Now what

The main thing to watch with Bluebird isn't related to what the Fed does, though. Instead, investors should keep their eyes on the company's pipeline progress. In particular, the company hopes to file for U.S. and European approvals of Lenti-D in treating cerebral adrenoleukodystrophy by the end of 2020. Bluebird and its partner, Bristol Myers Squibb, also await U.S. approval of ide-cel in treating multiple myeloma.

Keith Speights owns shares of Bristol Myers Squibb. The Motley Fool owns shares of and recommends Bluebird Bio and Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$6.58 (-3.66%) $0.25
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.13 (-0.54%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.